Yes, Isolated Small Bowel Transplantation is Well-Documented in Adults with Short Bowel Syndrome
Isolated small bowel transplantation is an established procedure for adult patients with short bowel syndrome who develop life-threatening complications from intestinal failure or total parenteral nutrition (TPN) therapy. The procedure has been recognized by Medicare since 2001 as standard of care for patients with small bowel and gut failure 1.
World Experience and Documentation
The 2003 Intestinal Transplant Registry documented 923 patients who received 989 intestinal transplantations across 19 countries, demonstrating this is not merely theoretical but widely practiced 1. The registry data showed 1-year survival rates comparable to liver transplant recipients, with most recipients achieving full nutritional autonomy and discontinuation of TPN 1.
Types of Transplants Performed
In adult intestinal transplantation, three graft configurations exist 2:
- Isolated small bowel transplantation (the specific procedure you're asking about)
- Combined liver and small bowel transplantation
- Multivisceral transplantation
For isolated small bowel transplants, the graft length ranges between 1.5-2 meters, anastomosed to the recipient's duodenum or remnant proximal jejunum, with vascular anastomoses performed directly on the aorta 2.
Specific Case Series Evidence
A 2007 study reported 25 consecutive isolated intestinal transplants in adult patients over 5 years, with median age 36.3 years 3. The two-year patient survival rate was 80% and five-year survival was 66%, with 16 grafts functioning properly without need for parenteral nutrition 3. Individual case reports further document successful isolated small bowel transplantation, including a 37-year-old male with massive gut infarction who achieved complete enteral diet and good quality of life by day 35 post-transplant 4.
Current Indications for Isolated Small Bowel Transplantation
According to Medicare-approved criteria and AGA guidelines, isolated intestinal transplants are indicated when patients fail TPN therapy due to 5:
- Impending or overt liver failure (elevated bilirubin/liver enzymes, splenomegaly, thrombocytopenia, varices, coagulopathy, hepatic fibrosis or cirrhosis)
- Thrombosis of major central venous channels (≥2 thromboses in subclavian, jugular, or femoral veins)
- Frequent central line-related sepsis (≥2 episodes of systemic sepsis per year, 1 episode of line-related fungemia, septic shock, or ARDS)
- Frequent severe dehydration
Critical Caveat on Liver Disease
Isolated intestine transplantation is NOT recommended in the setting of end-stage liver disease (ESLD) 5. When ESLD is present, combined intestine-liver transplant is required. However, carefully selected ESLD patients with significant residual intestine who are very likely to be weaned from TPN soon after transplant can achieve successful isolated liver transplantation 5.
Evolution and Current Status
The procedure became clinically viable after 1989 with the introduction of tacrolimus (FK-506), which ameliorated the formidable risks of allograft rejection and lethal host infection 1. Prior to this, the small bowel was considered a "forbidden organ" for transplantation due to massive lymphoid tissue, strong histocompatibility antigen expression, and microbial colonization 1.
Early referral for transplantation is associated with better survival outcomes 1. The ITR data showed better survival rates in patients waiting at home at the time of transplantation rather than hospitalized patients 1.
Common Pitfalls to Avoid
- Do not wait until end-stage liver disease develops before considering transplantation, as this eliminates the option for isolated small bowel transplant and forces combined liver-intestine transplantation with higher mortality
- Do not prematurely determine loss of venous access - alternatives include translumbar or transhepatic access to the IVC, and thoracotomy with direct intra-atrial catheter placement 5
- Recognize that isolated liver transplantation alone is not recommended for SBS patients with ESLD 5
The procedure is no longer investigational, with indications expanding as outcomes improve 6. While early survival rates approach those of other organ allografts, long-term graft survival remains suboptimal and requires continued research 6.